EMA Authorised: Sunitinib Accord (sunitinib) — Accord Healthcare S.L.U.

View source ↗

Summary

The European Medicines Agency authorised Sunitinib Accord for the treatment of gastrointestinal stromal tumors, renal cell carcinoma, and neuroendocrine tumors,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Neuroendocrine Tumor
• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib Accord (sunitinib)

Snippet

Status: Authorised. Therapeutic area: Gastrointestinal Stromal Tumors;Carcinoma, Renal Cell;Neuroendocrine Tumors. MAH: Accord Healthcare S.L.U.. Decision date: 26/11/2025